The aim of the study protocol is to measure product-specific COVID-19 vaccine effectiveness to prevent transmission of SARS-CoV-2 infection from healthcare workers to their contacts, which can be either other patients or healthcare workers, in healthcare settings.
In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.
This document describes how to strengthen surveillance in hospital settings for the identification of severely affected patients infected with avian influenza virus in the EU/EEA.
This document aims to collate and present the lessons identified from the public health stakeholders who responded to the COVID-19 pandemic. It is intended to serve as input for countries revising their pandemic or emergency preparedness plans.
Since 16 May 2022, and as of 4 April 2023, 21 170 cases of mpox (formerly known as monkeypox) have been reported by countries within the European Union/European Economic Area (EU/EEA).
This document offers an overview of the available scientific evidence and epidemiological situation and provides public health considerations to support discussions and decisions on the planning and implementation of COVID-19 vaccination campaigns for 2023.
This document aims to support countries in designing after-action reviews (AARs) of the public health response to COVID-19. It has been designed to draw upon pre-existing ECDC guidance and follows a methodological approach combining interactive workshops and interviews. The Annexes feature practical implementation tools.
This update reports on one of the ECDC multi-country studies that is centred around the hospital setting and severe disease, with the aim of assessing vaccine effectiveness against severe acuterespiratory infection (SARI) due to laboratory-confirmed SARS-CoV-2 within the ECDC VaccineEffectiveness, Burden and Impact Studies infrastructure (VEBIS) [1,2].
High levels of community transmission and the co-circulation of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus (RSV) and others can increase pressure on healthcare systems.
This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States.